TOKYO, Dec 1, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN, […]
TOKYO, Sep 12, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today results from a post hoc analysis of three randomized, pivotal, Phase 3 studies (EMBRACE trial/Study […]
TOKYO, Dec 6, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered eribulin mesylate […]
SINGAPORE – An orally consumed anti-cancer drug known as Bexarotene offers new hope to patients with triple-negative breast cancer (TNBC) – an aggressive form of breast cancer that appears more […]
SINGAPORE – For 15 days from when Vianna was born on March 17, her mother, Ms Vivienne Low, 35, could only touch the infant’s tiny hands and watch her fight for […]
